Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00073918 · FLOW

Participant flow

Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma · Source last updated 2017-08-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    RADIOIMMUNOTHERAPY: Patients receive a test dose of iodine I 131 tositumomab IV on day -24 to determine biodistribution. Patients then receive therapeutic iodine I 131 tositumomab IV over approximately 40-60 minutes on day -14 and are entered into radiation isolation until day -4. CHEMOTHERAPY: Patients receive etoposide IV on day -4 and cyclophosphamide IV on day -2. AUTOLOGOUS STEM CELL TRANSPLANTATION: Patients undergo autologous peripheral blood stem cell transplantation on day 0. cyclophosphamide: Given IV etoposide: Given IV iodine I 131 tositumomab: Given IV quality-of-life assessment: Ancillary study peripheral blood stem cell transplantation: Undergo ASCT given via central catheter
    id
    FG000
    title
    Treatment (Radio Labeled Monoclonal Antibody, Chemotherapy)
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Eligibility requirement not met - HAMA+
    2. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Rapid disease progression
    3. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Eligibility requirement not met-low CD20
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        111
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        107
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        4
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    RADIOIMMUNOTHERAPY: Patients receive a test dose of iodine I 131 tositumomab IV on day -24 to determine biodistribution. Patients then receive therapeutic iodine I 131 tositumomab IV over approximately 40-60 minutes on day -14 and are entered into radiation isolation until day -4. CHEMOTHERAPY: Patients receive etoposide IV on day -4 and cyclophosphamide IV on day -2. AUTOLOGOUS STEM CELL TRANSPLANTATION: Patients undergo autologous peripheral blood stem cell transplantation on day 0. cyclophosphamide: Given IV etoposide: Given IV iodine I 131 tositumomab: Given IV quality-of-life assessment: Ancillary study peripheral blood stem cell transplantation: Undergo ASCT given via central catheter
    id
    FG000
    title
    Treatment (Radio Labeled Monoclonal Antibody, Chemotherapy)
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Eligibility requirement not met - HAMA+
    2. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Rapid disease progression
    3. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Eligibility requirement not met-low CD20
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        111
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        107
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        4
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice